Difamilast, sold under the brand name Moizerto among others, is a medication used for the treatment of atopic dermatitis. Difamilast is a non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor. Difamilast was discovered and developed by Otsuka Pharmaceutical.
Difamilast was approved for medical use in Japan in September 2021, and in the United States in February 2026.
Difamilast is indicated for the topical treatment of people with mild to moderate atopic dermatitis.
Difamilast was approved for medical use in Japan in September 2021, and in the United States in February 2026.
Difamilast is the international nonproprietary name.
Difamilast is sold under the brand names Moizerto (JP) and Adquey (US).